AllDocs -> cancers

Targeting lipid raft-mediated LPA signaling by avicins in ovarian cancer Zhi-Xiang Xu, Yiling Lu, Vasla Haridas, Mandi Murph, Gordon B. Mills, and Jordon Gutterman (Department of Molecular Therapeutics, UTMDACC) Background and Hypotheses: Ovarian cancer is the most frequent cause of gynecologic cancer -related mortality in women. The overall 5-year survival of ovarian carcinoma is less than 30%, creating a pressing need to understand its biology and develop effective and less toxic therapies for ovarian cancer . Recent work suggests that lysophosphatidic acid (LPA) plays a central role in the etiology of ovarian cancer . LPA binds to several G protein-coupled receptors (GPCRs), which can activate signaling pathways involved in the control of cell growth, including the Ras/mitogen-activated protein kinase (MAPK) pathway and phosphoinositide 3-kinase (PI3K) pathway, which have been implicated ...

Imaging Ovarian Cancer Specific Gene Expression In Vivo Vikas Kundra, M.D., Ph.D. Page 2 Vikas Kundra, M.D., Ph.D. Although effective therapies for ovarian cancer have been developed, disease recurrence is common. Primary and recurrent disease most commonly present as intraperitoneal implants. New methods, such as gene therapy are being developed primarily for therapy, but there is potential for diagnosis as well. However, many gene therapy protocols have not been successful, and a major reason for this is the lack of effective methodologies for evaluating the degree of gene expression in the target tumor. Like drug therapy, gene expression tends to increase with time and then either plateau, or much more commonly, wane. If the organ of interest is static in size, comparison may be performed over time. Tumors, however, present a special case because during the course ...

Descriptive Epidemiology of Ovarian Cancer in the United States, 1992-1997 CANCER (Supplement) 2003(May15);97/10:2615-2706. Descriptive Epidemiology of Ovarian Cancer in the United States, 1992-1997 Marc T. Goodman and Holly L. Howe Ovarian cancer is relatively uncommon, and therefore little has been published to date regarding racial or ethnic variations in the incidence or mortality of this malignancy. As the U.S. population becomes more diverse, the interest in health problems and disparities in outcomes among minority and economically disadvantaged groups will continue to increase. In this supplement, the authors focus on epidemiology, pathology and classification issues, multiple primary tumors, staging, and incidence and mortality for race/ethnic groups. The authors also focused on epidemiologic differences between borderline tumors of low malignant potential and carcinomas. ...

FY01 Peer Reviewed Medical Research Program Peer Reviewers Peer Reviewers Degree Institution/Affiliation Aaronson, Lauren S. Ph.D., R.N., F.A.A.N. University of Kansas Alexander, Dale E. Ph.D. University of Houston Ashford, David A. D.V.M., M.P.H., D.Sc. Centers for Disease Control and Prevention Azad, Abdu F. Ph.D. University of Maryland School of Medicine Bacchetti, Peter Ph.D. University of California Becan-McBride, Kathleen E. Ed.D. University of Texas at Houston Bergeron, Michael F. Ph.D. Medical College of Georgia Bliska, James B. Ph.D. State University of New York at Stony Brook Brodell, Robert T. M.D. Northeastern Ohio Universities Medical College Brown, Nigel L. Ph.D. University of Birmingham Bruce, Margaret C. Sc.D. University of Kentucky ...

Rebecca Whelan Oberlin College Development of Assays for Biomarkers of Ovarian Cancer Ovarian cancer presents at an advanced stage in more than 75% of patients, with a five-year survival rate of 30%. If it is diagnosed in stage I, while the cancer is localized to the ovary, the five-year survival rate is 95%. These statistics suggest great potential advantages to be gained from improved early detection of ovarian cancer . A promising area for early detection is the development of assays for serum biomarkers that are expressed in ovarian cancer , even in early-stage disease. Ideally these assays will exhibit high sensitivity, robust performance, ease of use in a clinical setting, and low cost. Current research in our laboratory focuses on two areas: the development of novel antibody-based detection methods for biomarkers of ovarian cancer and the selection and application of single- ...

Use of this content is subject to the Terms and Conditions of the MD Consult web site. Hematology/oncology Clinics of North America Volume 17 Number 4 August 2003 Copyright © 2003 W. B. Saunders Company Immunologic principles and immunotherapeutic approaches in ovarian cancer Keith L. Knutson , PhD a , * Tyler J. Curiel, MD, MPH b Lupe Salazar, MD a Mary L. Disis, MD a a Tumor Vaccine Group 1959 Northeast Pacific Street Box 356527 HSB BB1321 University of Washington Seattle, WA 98195, USA b Hematology and Medical Oncology Tulane University Medical Center 1430 Tulane Avenue SL78 New Orleans, LA 70112, USA Immune-based therapies for the treatment of ovarian cancer now are being designed to circumvent specific biologic problems that have been identified ...

CODE: PACLICARBO CCO Formulary Revised February, 2006 A REGIMEN NAME PACLITAXEL-CARBOPLATIN (PACLICARBO) Chemotherapy Cancer Ovarian Cancer (Stage II, III, or IV) Primary Peritoneal Cancer Fallopian Tube Cancer Curative Regimen Category CORE, RESTRICTED CCO: standard therapy endorsed by the Disease Site Group and a re gimen which requires eligibility confirmation for reimbursement by the CCO New Drug Funding Program. Indications and Rationales First line postoperative chemotherapy regimen for newly diagnosed stage II-IV epithelial ovarian cancer . B DRUG REGIMEN PACLITAXEL ( Round to nearest 3 mg) 135-175/m 2 IV over 3 hours (give first) Day 1 Give Paclitaxel before Carboplatin CARBOPLATIN ...

Early detection is key to overcoming ovarian cancer By Andrea Yevchak The new year has started with the hope of resolutions ringing true and the possibility of a new start and new adventures in life. What many women and their families may not be looking forward to is ovarian cancer , as approximately 22,000 new cases are diagnosed each year. Affecting approximately 1 in 57 women, ovarian cancer is not as common as breast cancer , which affects 1 in 7 women, but it is considered more deadly, because of a much higher percentage of terminal cases. According to the American Cancer Society, ovarian cancer accounts for only 3 percent of all cancers among women, yet ranks fourth as a cause of their deaths from cancer . The American Cancer Society statistics for ovarian cancer estimate that annually there are about 22,220 new cases and 16,210 deaths. Ovarian cancer is treatable ...

Is there hope for early detection of ovarian cancer ? We know that cancer , like most diseases, is more easily treated when found early. Early, however, can mean many things. In cancer detection it means that the tumor isn’t very large, the cells haven’t grown very deep into the tissue, or that they have not yet spread from the original location to other places in the body. Prevention and early detection depend greatly on an individual to heed warnings (such as staying out of the sun to prevent skin cancer ); following screening guidelines according to age (such as receiving a pap smear, colonoscopy, or mammogram); and paying attention to changes, signs, and symptoms in our own body (such as feeling a breast lump). In the case of screening we depend on doctors, scientists, and machines to let us know if we are healthy. Of course we want the best tools possible. The pap smear, for example, identifies abnormal ...

Data Sheet CA125 ( Ovarian Cancer Antigen) mouse monoclonal antibody NCL-CA125 Intended Use FOR RESEARCH USE ONLY . Specificity Repetitive protein determinant expressed in the protein core of the CA125 human ovarian cancer antigen. Clone Ov185:1 Ig Class IgG1 Antigen used A partially purified mucin fraction from a pool of cancer tissue from patients with epithelial ovarian for immunisations cancer . Hybridoma partner Mouse myeloma (P3x63-Ag8.653). Preparation Lyophilised and purified Ig fraction presented in PBS (pH7.6) with 1% BSA containing 15mM sodium azide. Reconstitute with the volume of sterile distilled water indicated on the vial label. Effective on frozen tissue Yes Effective on paraffin wax Yes (using the high temperature antigen unmasking technique: see ...

Data Sheet CA125 ( Ovarian Cancer Antigen) ready to use - prediluted liquid mouse monoclonal antibody RTU-CA125 Intended Use FOR RESEARCH USE ONLY . Specificity Repetitive protein determinant expressed in the protein core of the CA125 human ovarian cancer antigen. Clone Ov185:1 Ig Class IgG1 Antigen used A partially purified mucin fraction from a pool of cancer tissue from patients with epithelial ovarian for immunisations cancer . Hybridoma partner Mouse myeloma (P3x63-Ag8.653). Preparation Purified Ig fraction diluted in 5% horse serum in PBS containing 12mM sodium azide. Volume as indicated on vial label. Effective on frozen tissue Yes Effective on paraffin wax Yes (using the high temperature antigen unmasking technique: see overleaf). embedded tissue Recommendations ...

Annual Report 2003 Ovarian Cancer Project Cancer Research Program, Garvan Institute of Medical Research; and Gynaecological Cancer Centre (GCC), Royal Hospital for Women. General The collaboration between the GCC and the Cancer Research Program of the Garvan Institute has just completed its 5 th year, however 2003 was the first year in which we established a full-time research team to fully utilise the two major resources established over the past few years viz., the patient Tissue Bank and Clinical Database, and the data from our comprehensive study that determined which of the 30,000 genes in the human genome were abnormally activated in ovarian cancer . Patients We continued to recruit patients undergoing treatment at the GCC to our research study, bringing the number of patients entered in the Tissue Bank and Clinical Database to 498. This is one of our major resources ...

Centers for Disease Control and Prevention Ovarian Cancer Control Initiative The Ovarian Cancer National Alliance (the Alliance) works to increase public and health professional knowledge of ovarian cancer and advocates for increased resources to support research and public awareness. As part of the Alliance’s efforts to prevent suffering and decrease mortality from ovarian cancer , we advocate for enhanced federal investment in the Centers for Disease Control and Prevention (CDC) Ovarian Cancer Control Initiative. The Ovarian Cancer National Alliance respectfully calls upon Congress to provide $ 7.5 million to the Ovarian Cancer Control Initiative in Fiscal Year (FY) 2007. Ovarian cancer will claim more than 15,300 lives each year, making it the fourth deadliest cancer for women. Every American woman is at risk for this fatal disease, and one in 57 will develop it ...

Ovarian cancer is the eighth most common cancer in Australian women. If diagnosed and treated early the survival rate is very high. However, due to a lack of obvious symptoms, only about 20% of ovarian cancers are detected early . Each year, about 1,173 women are diagnosed with ovarian cancer in Australia. About 731 will die from the disease. In the ACT 13 women are diagnosed with cancer of the cervix each year, and 11 will die from the disease. What are the ovaries? The ovaries are two small oval shaped organs, that are part of the female reproductive system. They are found inside the pelvic cavity, one on each side of the uterus (womb). The ovaries contain germ cells which eventually develop into eggs (ova). Amature egg is released from the ovary each month and passes through one of the two fallopian tubes, where it may be fertilised by a male sperm. If it ...

of the file http://www.medlockconsulting.com/images/Ovarian_Cancer.doc . G o o g l e automatically generates html versions of documents as we crawl the web. To link to or bookmark this page, use the following url: http://www.google.com/search?q=cache:s3RsU64XUdsJ:www.medlockconsulting.com/images/Ovarian_Cancer.doc+ovarian+cancer+filetype:pdf+OR+filetype:doc+OR+filetype:ppt+OR+filetype:xls+OR+filetype:rtf&hl=it&ct=clnk&cd=196&lr=lang_en Google is neither affiliated with the authors of this page nor responsible for its content. These search terms have been highlighted: ovarian cancer 1186 Hopkins Scientists Use Blood Proteins To Detect Ovarian Cancer Johns Hopkins Kimmel Cancer Center researchers have designed a blood test to detect ovarian cancer using three proteins found in common in the blood of women with the disease. Their preliminary studies with ...

Volume 4, Issue 1 January, 2006 In this issue.. • Articles: o New Ovarian Cancer Study Offers Hope and Highlights Risks o The Advocate Institute Announces Second "Focus on Research" Course o Videotaping to Enhance Clinical Trial Awareness o Patient Education Booklet Available from NCI “Providing Your Tissue for Research" • Features : o Fact Sheets o Research Advocacy Network Activities Report Calendar Awareness Events o Please Donate New Ovarian Cancer Study Offers Hope and Highlights Risks Research demonstrating an advance in the treatment of late-stage ovarian cancer was published in the January 5, 2006 issue of the New England Journal of Medicine (NEJM). The article details the findings of a study led by Dr. Deborah Armstrong of the Sidney Kimmel Comprehensive Cancer Center ...

CLINCIAL TRIAL UPDATE Prima BioMed Completes Initial Recruitment of Phase IIa Ovarian Cancer Trial Wednesday, 12 October 2005, Melbourne, Australia: Prima BioMed (ASX: PRR) has completed initial recruitment of its Phase IIa clinical trial in ovarian cancer at the Austin Hospital. The completion of the recruitment of the 20 patients represents an important milestone for the clinical trial using dendritic cell therapy. In order to obtain stronger data for the final evaluation report, the principal investigator for the trial, in consultation with Prima's Scientific Advisory Panel (SAP), sought and received approval from the Human Research Ethics Committee at the Austin Hospital to supplement the 20 patients already recruited. Up to a further ten patients will be invited to participate, allowing the company to collect additional data with only a minimal extension of the trial length. Cancer ...

Last revised: 10/11/2005 UM Comprehensive Cancer Center Patient Education Document #0036 Nov05 Ed. Online version: http://www. cancer .med.umich.edu/learn/percpathways.htm University of Michigan Comprehensive Cancer Center Patient Education Resource Center (PERC) INFORMATION GUIDE Ovarian Cancer The purpose of this information guide is to help patients newly diagnosed with ovarian cancer and their families to find sources of information and support. This list is not meant to be comprehensive, but rather to provide starting points for information seeking. The materials can be found at the Patient Education Resource Center (PERC) of the University of Michigan Comprehensive Cancer Center in room B1-361. Brochures Available free at the Patient Education Resource Center on Level B-1 • National Cancer Institute. What You Need ...

Ovarian Cancer Ovarian cancer is cancer that begins in a woman's ovaries, located on each side of the pelvis. More than 22,000 news cases were estimated to be diagnosed in 2005 and about 16,000 women were expected to die from the disease. Tumors in the ovary are named for the type of cell from which they begin: germ cell tumors; stromal tumors; epithelial tumors; and primary peritoneal carcinoma PREVENTION While there is no way to prevent ovarian cancer , but research has shown that some things may help reduce risk: • The use of oral contraceptives • Tubal ligation or hysterectomy • Pregnancy and breast-feeding: • A diet high in plant foods like vegetables. RISKS Some of the risk factors for the most common (epithelial) type of ovarian cancer are • Aging • Women who have never had children • Long term use of fertility drugs and hormone ...

78 Title 3—The President Proc. 7810 Proclamation 7810 of September 10, 2004 National Ovarian Cancer Awareness Month, 2004 By the President of the United States of America A Proclamation Ovarian cancer affects thousands of Americans each year. During this time of tremendous medical breakthroughs, we are seeing progress in the effort to overcome this disease, but our work is not finished. National Ovarian Cancer Awareness Month provides an opportunity for our citizens to learn more about early detection and treatment for this deadly cancer . Although new cases of ovarian cancer in the United States have been de- creasing for more than a decade, the American Cancer Society estimates that about 25,000 women will be diagnosed this year and over 16,000 will die from the disease. Family and personal history can affect the likelihood of developing ...

36 TRACKING A LADY KILLER: OVARIAN CANCER SILENT by Scott Still “I’m sorry, but the test came back positive. You have ovarian cancer .” These are among the most dreaded words a woman may hear from her doctor. However, the best chance of beating this affliction, which accounts for four percent of all cancers among women and ranks fifth among female cancer -related deaths, is obtaining this diagnosis as early as possible in the development of the disease; early detection is crucial to improving chances of survival. Page 2 Dr. Michael Tainsky and Dr. Sorin Draghici. Page 3 This is why the research that Wayne State University’s Dr. Michael Tainsky is doing is so critical. The work of Dr. Tainsky and his interdisciplinary team at the Barbara Ann Karmanos Cancer Institute draws upon ...

FOR IMMEDIATE RELEASE CONTACT: WEDNESDAY, JANUARY 4, 2006 Marsha Wilson 301-320-3342 301-332-0117 (c) Intraperitoneal Chemotherapy Administration Prolongs Survival for Women with Advanced Ovarian Cancer Findings Indicate That Expertise in Management of Intraperitoneal Catheters is an Important Issue in Administration of IP Chemotherapy CHICAGO (January 4, 2006) – A study featured in this month’s edition of Gynecologic Oncology examines the challenges associated with the administration of intra-abdominal chemotherapy, also known as intraperitoneal (IP) chemotherapy. This is a companion study to a paper released today in the New England Journal of Medicine showing longer survival for women who received IP chemotherapy compared with those who received the standard intravenous (IV) regimen. The New England Journal of Medicine study, “Intravenous Cisplatin and ...

Southwest Oncology Group Operations Office 14980 Omicron Drive • San Antonio, TX 78245-3217 • Telephone 210-677-8808 • FAX 210-677-0006 • http://swog.org FOR IMMEDIATE RELEASE Jan. 6, 2006 Contact: Rosanne Fohn Phone: 210-677-8808 E-mail: rfohn@swog.org Southwest Oncology Group contributes to new NCI recommendation for treating advanced ovarian cancer The Southwest Oncology Group conducted studies that have collectively contributed to the evidence that the delivery of chemotherapy delivered both intravenously and into the abdominal cavity after surgery improves overall survival for women with advanced ovarian cancer . On Jan. 5, the National Cancer Institute issued an announcement recommending the combined regime. Data show that overall survival is improved by about a year. An intergroup trial led by the Southwest Oncology Group and a second trial ...

EMBARGOED FOR RELEASE January 4, 2006 5:00 p.m. EST Media Contact: Lucha Ramey, (502) 562-8022, luchara@ulh.org Ovarian Cancer • Ovarian cancer is the fourth leading cause of cancer death among women. It most often occurs in women in their 50's. • Ovarian cancer accounts for approximately four percent of all women’s cancers and is the fourth leading cause of cancer -related death among women in the United States. • In 2005, an estimated 22,000 women were diagnosed with ovarian cancer , and more than 16,000 women died from the disease. The incidence rate for ovarian cancer has been slowly declining since the early 1990s. • Some ovarian cancers are caused by inherited gene mutations. The genes in cells carry the hereditary information that is received from the parents. Three hereditary patterns have been identified: ovarian cancer alone, ...

OVARIAN CANCER RESEARCH FUND, INC. OVARIAN CANCER RESEARCH TRAINING PROGRAMS OF EXCELLENCE __ 2006 The OVARIAN CANCER RESEARCH TRAINING PROGRAMS OF EXCELLENCE award provides funding for trainees who are working under the supervision of a mentor who is a recognized leader in the field of ovarian cancer research. Trainees may be involved in either laboratory, clinical or epidemiology research. Those eligible to apply include: 1) Clinical fellows (Gynecologic Oncology, Medical Oncology, etc.) 2) Post-doctoral fellows Awards will be made to approximately six individuals working in institutions with well-developed ovarian cancer research programs. In addition to the strength of the research environment and project proposal, selection criteria include the trainee’s prior academic track record and the likelihood of them pursuing a research career. The research plan ...

Things to look for are: u Pelvic or abdominal discomfort, such as constant fullness or bloating u Unexplained weight gain or loss u Fatigue or difficulty breathing u Gas, nausea or indigestion u Changes in bladder or bowel habits u Unusual vaginal bleeding u Pain during intercourse u Fever, backaches or cramps Every three and a half hours,another Canadian woman is diagnosed with ovarian cancer . To learn more call 1 800 749 9310 Younger Women and Ovarian Cancer Page 2 How to tell others “ Under the shock of the situation, I had to explain to my husband, daughter, parents and friends a medical situation that I did not fully understand myself. ” France M., diagnosed at age 34 Many women are alone ...

Ovarian Cancer – Facts and Myths Ovarian Cancer – Facts and Myths Gary S. Leiserowitz, M.D. Gary S. Leiserowitz, M.D. Associate Professor and Associate Professor and Chief Chief Division of Gynecologic Division of Gynecologic Oncology, UCDMC Oncology, UCDMC Page 2 Ovarian Cancer Ovarian Cancer What is ovarian cancer ? What is ovarian cancer ? Ovarian cancer arises from cells within Ovarian cancer arises from cells within the ovary the ovary Ovarian cancer is the leading cause of Ovarian cancer is the leading cause of death among female genital cancers death among female genital cancers 25,000 new cases /year of ovarian 25,000 new cases ...

PREOPERATIVE OVARIAN CANCER DIAGNOSIS USING NEURO-FUZZY APPROACH E.O. Madu, V. Stalbovskaya, B. Hamadicharef, E.C. Ifeachor S. Van Huffel, D. Timmerman Univ. of Plymouth, UK KU Leuven, Belgium ABSTRACT In this paper, we propose a neuro-fuzzy model for preoperative prediction of malignancy in ovarian tumours. The model is intended to form part of a reliable preoperative tool to discriminate between benign and malignant ovarian tumours to help clinicians decide the most appropriate form of treatment for patients. An aim of our work is to find a model that is understandable, practicable and capable of achieving accurate diagnosis. In this paper, we present our initial attempts to develop such a model using the Adaptive Network based Fuzzy Inference System (ANFIS). Our model predicts ovarian cancer malignancy using demographic, serum tumour marker and ultrasound- ...

Ovarian Cancer Canada Page 2 Our mission Every three and a half hours, another Canadian woman is diagnosed with ovarian cancer . A woman we love, a woman we care for, women who will be Ovarian Cancer Canada – the voices for her life. Ovarian Cancer Canada is an alliance of women diagnosed with ovarian cancer , their supporters, and medical and health care experts. We are united by one common factor: we have all been touched by ovarian cancer . And we share a goal: the eradication of the disease. Our mandate We support women with ovarian cancer and their families, women in general and the broader community through awareness campaigns and activities, the creation and dissemination of education materials appropriate in language, format and content for ...

Isoform-Specific Targeting of Cancer -Associated Genes by Small Interfering RNA in Ovarian Carcinoma Lin Zhang, George Coukos Center for Research on Reproduction and Women’s Health Abramson Family Cancer Research Institute University of Pennsylvania School of Medicine Page 2 RNA interference ( RNA interference ( RNAi RNAi ), a sequence ), a sequence - - specific specific post post - - transcriptional gene silencing mechanism transcriptional gene silencing mechanism Page 3 Exon Exon - - Specific Specific RNAi RNAi • • The majority of metazoan genes encode pre The majority of metazoan genes encode pre - - mRNAs that are mRNAs that are subject to alternative splicing. subject to alternative splicing. ...